CoreCap Advisors’s Filana Therapeutics FLNA Stock Holding History

CoreCap Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-92	Closed	-$138	–	3182
2025 Q1	$138	Buy	+92	New	+$232	﹤0.01%	3034

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

CoreCap Advisors's FLNA Position: Q2 2025 in Review

CoreCap Advisors sold out of Filana Therapeutics (FLNA) in Q2 2025, closing a stake of 92 shares — an estimated $138 sold.

CoreCap Advisors first reported a position in FLNA in Q1 2025 and held it in 1 quarter. The position peaked at $138 in Q1 2025. 97 funds tracked by Wall St. Rank hold FLNA as of Q2 2025.

CoreCap Advisors reported no remaining Filana Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 92 Filana Therapeutics shares in Q2 2025, an estimated $138.
CoreCap Advisors first reported a position in Filana Therapeutics in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Filana Therapeutics position peaked at $138 in Q1 2025.
97 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.